Sign in
CompletedPhase 2

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

Key facts

Who runs it
Ionis Pharmaceuticals, Inc.
Where
Boca Raton, Columbus, Council Bluffs, Evanston, Flint, Gurnee, Lansdale, Las Vegas, Lincoln, Little River, Louisville, Manassas, Mesquite, Miami, Montclair, New Port Richey, Norfolk, Rapid City, Tullahoma, and Winter Park, United StatesSee the 21 sitesAlso in 1 other country, 3 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
154 people enrolled
Started
9 May 2022
Ended
21 Dec 2023
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Olezarsen
  • Placebo
Record updated
23 April 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Aged ≥ 18 years at the time of informed consent
  • Fall into at least 1 of the following groups (a or b):; Hypertriglyceridemia with fasting TG ≥ 150 mg/dL (1.69 millimoles per liter [mmol/L]) and < 500 mg/dL (5.65 mmol/L) with either clinical diagnosis of atherosclerotic cardiovascular disease (ASCVD) or at increased risk for ASCVD; Severe hypertriglyceridemia with fasting TG ≥ 500 mg/dL (5.65 mmol/L)
  • Participants must be on standard-of-care (SOC), lipid-lowering medications per local guidelines
  • Participants must be willing to comply with diet and lifestyle recommendations as able

Who cannot take part

  • Acute coronary syndrome or stroke/transient ischemic attack (TIA) within 6 months prior to Screening
  • Major surgery, peripheral revascularization, or non-urgent percutaneous coronary intervention (PCI) within 3 months prior to Screening, or upcoming planned major surgery or major procedure (e.g., arterial revascularization) during the course of the study
  • Active pancreatitis within 4 weeks prior to Screening
  • Diabetes with any of the following:; Newly diagnosed within 12 weeks of screening; Hemoglobin A1C (HbA1c) ≥ 9.5% at Screening; Change in basal insulin regimen > 20% within 3 months prior to Screening; For participants with type 1 diabetes: episode of diabetic ketoacidosis, or ≥ 3 episodes of severe hypoglycemia within 6 months prior to Screening

Where in United States

Also in 1 other country, 3 sites

  • Excel Medical Clinical Trials, LLCBoca Raton, United States
  • IACT HealthColumbus, United States
  • West Broadway ClinicCouncil Bluffs, United States
  • Evanston Premier Healthcare ResearchEvanston, United States
  • Aa Mrc LlcFlint, United States
  • Clinical Investigation SpecialistGurnee, United States
  • Green and Seidner Family Practice AssociatesLansdale, United States
  • Clinical Research of South NevadaLas Vegas, United States
  • Palm Research Center IncLas Vegas, United States
  • Clinical Trials ResearchLincoln, United States
  • Main Street Physicians Care WaterwayLittle River, United States
  • Louisville Metabolic and Atherosclerosis Research Center (L-MARC)Louisville, United States
  • Manassas Clinical Research CenterManassas, United States
  • Southern Endocrinology AssociatesMesquite, United States
  • De La Cruz Research CenterMiami, United States
  • Catalina Research Institute, LLCMontclair, United States
  • Suncoast Clinical Research, Inc.New Port Richey, United States
  • York Clinical Research LLCNorfolk, United States
  • Health ConceptsRapid City, United States
  • Tennessee Center for Clinical TrialsTullahoma, United States
  • Research Physicians Network AllianceWinter Park, United States

About the trial

What the trial wants to find out

The purpose of the study was to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the proportion of participants who achieve different thresholds in fasting TG. Other objectives were to evaluate the effect of olezarsen on percent change in fasting apolipoprotein C-III (apoC-III), very low-density lipoprotein cholesterol (VLDL-C), remnant cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, total cholesterol (TC), apolipoprotein B (apoB), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein A-1 (apoA-1).

The 3 groups in the trial

  • PlaceboPlacebo, for comparison

    Participants received olezarsen-matching placebo, as a single subcutaneous (SC) injection, once every 4 weeks for 53 weeks treatment period.

  • Olezarsen 50 mgTreatment being tested

    Participants received olezarsen 50 mg, as a single 0.5 milliliters (mL) SC injection, once every 4 weeks for 53 weeks treatment period.

    Treatment: Olezarsen

  • Olezarsen 80 mgTreatment being tested

    Participants received olezarsen 80 mg, as a single 0.8 mL SC injection, once every 4 weeks for 53 weeks treatment period.

    Treatment: Olezarsen

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo-Controlled, Phase 2b Study of ISIS 678354 in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
Publications
Record updated
23 April 2026